Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials.

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials – Journal of Clinical Oncology

Commentaries:

Women at higher risk of severe adverse events from cancer therapy – eCancer

Women Face Higher Risk for Severe AEs From Cancer Therapy – HealthDay

Commentary on Twitter

? Women had worse toxicity from #chemotherapy, #immunotherapy or #TargetedTherapy as compared to men in analysis of multiple @SWOG #clinicaltrials ? https://t.co/PjmnyJROb4 #leusm #CRCSM #LCSM @DrJoeUnger @DrDawnHershman pic.twitter.com/BJPZQoaI6g

— Journal of Clinical Oncology (@JCO_ASCO) February 23, 2022